2024
Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story
Goldsweig A, Deng Y, Yao X, Desai N, Cohen D, Aronow H, Messé S, Ross J, Lansky A, Savitz S. Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010200. PMID: 38189127, PMCID: PMC10844981, DOI: 10.1161/circoutcomes.123.010200.Peer-Reviewed Original ResearchStroke/systemic embolismTransient ischemia attackPFO closureSystemic embolismIschemia attackRetrospective cohort studyTransient ischemic attackHalf of patientsOptumLabs Data WarehouseCommercial insurance enrolleesRegulatory approvalClinical trial publicationsIschemic attackRecurrent strokeCohort studyPatent foramenUnderwent closureAtrial fibrillationClinical trialsInsurance enrolleesDecompression illnessTrial publicationsOff labelPatientsProcedure volume
2023
ACC/AHA Hypertension Guidelines and CHA2DS2-VASc Up-Scoring in Patients With Atrial Fibrillation
Pundi K, Gosch K, Perino A, Jones P, Desai N, Maddox T, Turakhia M. ACC/AHA Hypertension Guidelines and CHA2DS2-VASc Up-Scoring in Patients With Atrial Fibrillation. JAMA Network Open 2023, 6: e2335722. PMID: 37751209, PMCID: PMC10523168, DOI: 10.1001/jamanetworkopen.2023.35722.Peer-Reviewed Original Research
2020
Outpatient Cost-effectiveness Study of Hyperkalemia Management
Desai N, Rowan C, Alvarez P, Fogli J, Coca S. Outpatient Cost-effectiveness Study of Hyperkalemia Management. Journal Of Cardiac Failure 2020, 26: s115. DOI: 10.1016/j.cardfail.2020.09.332.Peer-Reviewed Original ResearchOutpatient costsOptum's de-identified ClinformaticsEnd-stage renal diseaseMatched-cohort designData Mart DatabaseTreatment of hyperkalemiaMedicare Advantage populationCost-effectiveness studiesReal-world evidenceMEq/LCongestive HFHK cohortHyperkalemia managementPotassium bindersIndex dateCohort studyRenal diseaseOutpatient outcomesMean ageBaseline variablesInclusion criteriaPatiromerLarge cohortStudy populationCensoring event
2019
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Desai N, Rowan C, Alvarez P, Fogli J, Toto R. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients. Journal Of Drug Assessment 2019, 8: 2-2. PMCID: PMC6764378, DOI: 10.1080/21556660.2019.1658287.Peer-Reviewed Original ResearchContinuous exposureRenin angiotensin aldosterone system inhibitor therapyAldosterone system inhibitor therapyDevelopment of hyperkalemiaCornerstone of therapyRetrospective cohort studyOptum Clinformatics DataMartMEq/LNational Health InsuranceBinder therapyHK cohortHyperkalemia treatmentPotassium bindersRAASi therapyIndex dateCohort studyInhibitor therapyContinuation ratesMean ageDiagnosis codesITT groupCardiovascular diseaseClinformatics DataMartMedicare patientsPatiromer